Iceland· IS-EU/1/24/1793/001
Ryzneuta
A efbemalenograstim alfa product containing efbemalenograstimum alfa inn, registered in Iceland by Evive Biotechnology Ireland Limited. The same ATC class is registered in 9 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Efbemalenograstim alfa is registered in 9 of 19 countries.
Countries holding a registration under ATC L03AA18 (efbemalenograstim alfa), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 6 of them publish a price we can compare per daily dose
Efbemalenograstim alfa · ATC L03AA18
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Efbemalenograstimum alfa INN
- Manufacturer
- Evive Biotechnology Ireland Limited
- Country
- Iceland (IS)
- ATC code
- L03AA18
- ATC class
- Efbemalenograstim alfa
- Defined daily dose
- 20 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Efbemalenograstim alfa in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumRyzneuta 20 mgFisiopharma
- CzechiaRYZNEUTAFISIOPHARMA S.R.L., NUCLEO INDUSTRIALE, PALOMONTE
- PolandRyzneutaFisiopharma S.r.l.
- SwedenRyzneuta 20 mg Injektionsvätska, lösning i förfylld sprutaFisiopharma S.r.l.
- FinlandRyzneutaFisiopharma S.r.l.
- IrelandRyzneuta 20 mg solution for injectionFisiopharma SrL
- NetherlandsRyzneuta 20 mg oplossing voor injectieFisiopharma S.r.L.
- United StatesRYZNEUTAAcrotech Biopharma Inc
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Ryzneuta
- Norway · Ryzneuta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7345f389-5293-4e33-847b-5d1893657775 GET /v1/drugs/7345f389-5293-4e33-847b-5d1893657775?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn",
"source": "lyfjastofnun",
"atc_raw": "L03AA18",
"marketed": false,
"strength": "20 mg",
"ma_number": "EU/1/24/1793/001",
"substance": "Efbemalenograstimum alfa INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í blóðsjúkdómum og krabbameinslækningum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "45372"
}See everything about efbemalenograstim alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.